Patricia LoRusso

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Ian E. Krop, Patricia LoRusso, Kathy D. Miller et al. · Journal of Clinical Oncology · 2012 · 362 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Ian E. Krop, Tim Demuth, Tina Guthrie et al. · Journal of Clinical Oncology · 2012 · 317 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation

Adrian G. Sacher, Patricia LoRusso, Manish R. Patel et al. · New England Journal of Medicine · 2023 · 294 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

David S. Hong, Razelle Kurzrock, Aung Naing et al. · Investigational New Drugs · 2013 · 211 citations

Medicine, Oncology, Pharmacology +15